Pricing
  1. JP-listed companies
  3. Financials
  4. Cost of revenue

(4586)

Market cap
¥6.6B
P/E ratio
Medrex develops new pharmaceuticals using proprietary skin-patch delivery technology that improves drug effectiveness and reduces side effects.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCost of revenue (Million JPY)YoY (%)
Dec 31, 20251+300.00%
Dec 31, 20240-87.50%
Dec 31, 20232-8.36%
Dec 31, 20223+15.73%
Dec 31, 20212-42.17%
Dec 31, 20204-25.48%
Dec 31, 20195+114.94%
Dec 31, 20182-65.29%
Dec 31, 20177-7.19%
Dec 31, 20168-37.48%
Dec 31, 201512+30.06%
Dec 31, 20149

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat